Search clinical trials for: CLS001 (Omiganan)

Total 247 results

CStone Pharmaceuticals
Bayer

Completed

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Advanced Refractory Solid Tumors

Australia
Alector Inc.
GlaxoSmithKline

Enrolling by invitation

Continuation Study for Latozinemab

Neurodegenerative Diseases

Canada, United States, Belgium, France, Spain, Portugal, Germany, Italy, Netherlands, Sweden, United Kingdom
Alector Inc.

Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Amyotrophic Lateral Sclerosis

United States
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; Southwest Hospital, China; Daping Hospital...

Recruiting

Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hillel Yaffe Medical Center

Unknown

Coblation Versus Cold Adenoidectomy -Safety and Efficiency

Sleep Apnea, Obstructive
RenJi Hospital

Not yet recruiting

A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis

Decompensated Cirrhosis
Johnson & Johnson Surgical Vision, Inc.

Active, not recruiting

Proof-of-concept Study for a New Intraocular Lens, MODEL C0001

Cataract

France
Radboud University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Brain... and other collaborators

Recruiting

Promoting Resilience in Youth Through Mindfulness mEditation (PRYME)

Internalizing Problems

Netherlands
Binhui Biopharmaceutical Co., Ltd.

Not yet recruiting

OH2 Administered by Intratumoral Injection

Solid Tumor
Sun Yat-sen University

Active, not recruiting

IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck Neoplasm

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Stage III

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
BBraun Medical SAS

Completed

Multicenter Study to Describe the Performance of the AOS-C2001-B Device in Patients With Colostomy

Colostomy Stoma

France
Calibr, a division of Scripps Research

Active, not recruiting

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Transformed Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Primary Mediastinal Large B Cell Lymphoma | Follicular Lymphoma (FL) | Marginal Zone Lymphoma... and other conditions

United States
Xu jianmin

Unknown

A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

China
CStone Pharmaceuticals
Blueprint Medicines Corporation

Completed

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Shen Feng

Recruiting

Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Hepatocellular Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Gastric or Esophagogastric Junction Adenocarcinoma

China
Hutchison Medipharma Limited

Completed

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit / Hyperactivity Disorder

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Multiple Myeloma and Malignant Lymphoma

Japan
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Hematologic Diseases | Genetic Diseases, Inborn | Sickle Cell Disease | Hemoglobinopathies | Sickle Cell Anemia | Thalassemia | Beta-Thalassemia

United States, Italy, Germany, Saudi Arabia
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, Germany, Italy, United Kingdom, Canada
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Northern Jiangsu Province People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Neoadjuvant Therapy | Radiotherapy | Immunotherapy

China
Ascentage Pharma Group Inc.

Recruiting

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Advanced Solid Tumor

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS) (RePASS)

Head and Neck Cancer

China
Elucida Oncology
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)

Withdrawn

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML)

Acute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder

Japan
LaNova Medicines Zhejiang Co., Ltd.

Recruiting

A LM-302 Combined With Toripalimab Phase II Study

Gastric Cancer | Pancreatic Cancer

China
Peking University Cancer Hospital & Institute

Unknown

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Recruiting

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases | Hydroxyurea Failure | Hydroxyurea Intolerance

United States, Italy, United Kingdom, Germany
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease

Sickle Cell Disease | Hemoglobinopathies | Hematological Diseases

United States, Belgium, Canada, France, Germany, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated
CRISPR Therapeutics

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia

Hematologic Diseases | Genetic Diseases, Inborn | Hemoglobinopathies | Thalassemia | Beta-Thalassemia

United States, United Kingdom, Canada, Germany, Italy
Wan He

Recruiting

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer (PNACGEC)

Stomach Neoplasms

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Lymphoma | Lung Cancer

China
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Karolinska Institutet
deFair Medical AB

Active, not recruiting

Probiotics for Weight Loss

Overweight

Sweden
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Chimerix
Food and Drug Administration (FDA)

Withdrawn

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola (BCV EBOV)

Ebola Virus Disease
Third Military Medical University

Unknown

Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes

Diabetes | Taurine | Lower Extremity Artery Disease

China
Maruho Co., Ltd.

Unknown

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Seborrheic Dermatitis

Netherlands
Chimerix

Terminated

The Chimerix CMX001 Registry (CMX001)

Outcomes | Survival Rates

United States, Belgium, Canada

Search clinical trials for: CLS001 (Omiganan)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations